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ABSTRACT
India is one of a number of countries which impose a “local working” requirement on patented
inventions. This finds its source in sections 83, 84, and 89 of India’s Patent Act. A recent decision by
the Controller of Patents granting a compulsory license to Natco for a Bayer-patented anti-cancer
drug confirms that importation will not satisfy this requirement. Corporations seeking to produce
and market products for international sale will receive varying degrees of patent protection from
different nations. This comment proposes an amendment to the Agreement on Trade-Related
Aspects of Intellectual Property Rights (“TRIPS”) defining what local working requirements are
permitted, and requiring that nations meet and confer when making decisions on compulsory
licenses
against
foreign
patent-holders.
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INDIA’S USE IT OR LOSE IT: TIME TO REVISIT TRIPS?
LEVON BARSOUMIAN*
INTRODUCTION
Over the past hundred years, modes of shipping have improved.1 The world
population growth in that same time has provided a large market to buy and sell
goods.2 Lowering barriers to international trade is the World Trade Organization
(“WTO”).3 Intellectual property rights are crucial to international trade.4 Patent
rights are important to the international trade of goods.5 The Patent Cooperation
Treaty (“PCT”) and Agreement on Trade-Related Aspects of Intellectual Property
Rights (“TRIPS”) together form a framework for international patent prosecution and
patent protection.6 The TRIPS agreement has a pending amendment, the Doha
Ministerial Declaration of 2004.7
India is a rapidly developing country, with a growing population exceeding 1
billion.8 This puts India in an attractive position for trade with the United States.9
* © Levon Barsoumian 2012. Juris Doctor Candidate, May 2012, The John Marshall Law
School. B.S. Biomedical (Biochemical) Engineering, University of Southern California, 2006. I
would like to thank my wife for her patience and support, and the RIPL editorial staff. Any mistakes
in this article are my own.
1 See generally Liav Orgad, Illiberal Liberalism Cultural Restrictions on Migration and Access
to Citizenship in Europe, 58 AM. J. COMP. L. 53, 54–59 (2002) (discussing advent of cheap travel and
how it has contributed to immigration); see also Anna Gekht, Shared but Differentiated
Responsibility: Integration of International Obligations in Fight Against Trafficking in Human
Beings, 37 DENV. J. INT’L. L. & POL’Y. 29, 33 (2008) (noting advancements in transportation as
contributing to increases in human trafficking).
2 See U.N. POPULATIONS FUND, STATE OF THE WORLD POPULATION 2001 (2001), available at
http://www.unfpa.org/swp/2001/english/ch01.html#1c (noting that the population had doubled
between 1960 and 2001 to 6.1 billion); see also POPULATION REFERENCE BUREAU, WORLD
POPULATION
GROWTH
(2010),
available
at
http://www.prb.org/Educators/TeachersGuides/HumanPopulation/PopulationGrowth.aspx (outlining
population growth from ancient times to present day).
3 See generally Marrakesh Agreement Establishing the World Trade Organization, The Results
of the Uruguay Round of Multilateral Trade Negotiations, art. X, April 15, 1994, 1867 U.N.T.S. 154,
33 I.L.M. 1144 [hereinafter WTO Agreement].
4 See generally SHUBHA GHOSH ET AL., INTELLECTUAL PROPERTY:
PRIVATE RIGHTS, THE
PUBLIC INTEREST, AND THE REGULATION OF CREATIVE ACTIVITY 228–31 (Thompson/West 2007)
(describing historical development of patent rights and rights covered).
5 See Alice O. Martin & Sendil K. Devadas, Patents with an “I” = Patients, 188 ANN. HEALTH L.
261, 269–70 (2009) (noting that without a patent system, investors may stay away).
6 See Agreement on Trade-Related Aspects of Intellectual Property Rights, Marrakesh
Agreement Establishing the World Trade Organization, Annex 1C, Legal Instruments—Results of
the Uruguay Round, art. 17, Apr. 15, 1994, 33 I.L.M. 1125, 1869 U.N.T.S. 299 [hereinafter TRIPS],
available at http://www.wto.org/english/docs_e/legal_e/27-trips.pdf; see also Patent Cooperation
Treaty, June 19, 1970, 9 I.L.M 978.
7 See Declaration on the TRIPS Agreement and Public Health, WT/MIN(01)/Dec/2 P4 (Nov. 14,
2001) [hereinafter Doha Declaration].
8 CENT.
INTELLIGENCE AGENCY, THE WORLD FACTBOOK (2010), available at
https://www.cia.gov/library/publications/the-world-factbook/geos/in.html (noting Indian population
in excess of 1.1 billion as of July 2010 estimates).
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It is therefore important to have an understanding of the patent laws of India and
how they will apply to an American corporation seeking to do business in India.10
The focus of this comment is a provision in the Indian Patent Law which
requires a patent to be worked in the territory of India.11 If a patent is not worked in
the territory of India, compulsory license may be granted upon application and
approval by the patent controller.12 A compulsory license is defined by Black’s Law
Dictionary as a license created by statute that allows others to use an invention in
exchange for a reasonable royalty without the consent of the patentee.13 Working of
a patent is not defined within the text of the Indian Patent Law.14 A recent decision
of the Controller of Patents, however, has elucidated the meaning of the local
working requirement as it pertains to the Indian Patent Law.15 This comment will
focus on the impact of the local working requirement on an American corporation.
First, this comment will introduce and explain the respective patent laws of
India and the United States. The local working requirement will be introduced and
explained. Next, the comment introduces the TRIPS agreement, the PCT, and the
Doha Declaration will be introduced. The comment analyzes the TRIPS text and
TRIPS decisions in order to determine if a “use it or lose it” provision predicated on
local working is permitted by the TRIPS agreement. The comment presents a
revision to TRIPS as a solution to the uncertainty faced by a company seeking to
conduct work in India.
I. BACKGROUND
Over the past hundred years, the United States and India have become
important trade relations.16 With increased interaction between nations India and
the United States, having an understanding of the current relationship between two
countries and their patent laws become important.17

9 See generally Peter K. Yu, Access to Medicines, BRICS Alliances, and Collective Action, 34
AM. J. L. AND MED. 345, 348 (2008) (discussing the attractiveness of partnerships with BRICS
alliance countries).
10 See Susan Fyan, Pharmaceutical Patent Protection and Section 3(D): A Comparative Look at
India and the U.S., 15 VA. J. L. & TECH. 198, 217 (2010).
11 See The Patents Act, No. 39 of 1970, INDIA CODE (1999), § 84(1) (amended 2005).
[hereinafter Indian Patent Act].
12 Id.
13 BLACK’S LAW DICTIONARY (9th ed. 2009) (defining a compulsory license as “a statutorily
created license that allows certain people to pay a royalty and use an invention without the
patentee’s permission”). See generally Andrew C. Mace, TRIPS, eBay, and Denials of Injunctive
Relief: Is Article 31 Compliance Everything?, 10 COLUM. SCI. & TECH. L. REV. 232, 243–45 (2009).
14 See Indian Patent Act, § 84.
15 Natco Pharma. Ltd. & Bayer Corp. (Mar. 12, 2012) (India).
16 U.S. CENSUS BUREAU, REPORT ON U.S. INTERNATIONAL TRADE IN GOODS AND SERVICES
Exhibit 6a (2009) [hereinafter 2009 REPORT ON INT’L TRADE].
17 See Susan Fyan, Pharmaceutical Patent Protection and Section 3(D): A Comparative Look at
India and the U.S., 15 VA. J. L. & TECH. 198, 217 (2010).
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A. Trade between the United States and India
India is a major trade partner of the United States.18 In 2009, the United States
exported a total of $1.1 trillion in goods,19 importing $1.6 trillion in goods.20 In the
same time period, the United States exported $16.4 billion worth of goods and
services to India,21 while importing $21.2 billion worth of goods and services.22 In the
field of advanced technology products,23 a highly patent-dependent field,24 the United
States exported $244 billion worth of products,25 while importing some $300 billion
worth of products and services in 2009.26 The same year, India was the 15th ranked
importer to the United States.27 Patent protection can have a huge impact on two
nations that have extensive trade relationships with one another, and impact
manufacturing and marketing choices.28
Further complicating this picture is outsourcing. A large number of companies
in the United States develop their technologies domestically while outsourcing
manufacturing.29 To add to these companies, a large number of companies in the
United States also outsource product development processes overseas.30 Cheap
foreign labor overseas, inexpensive shipping, and improved trade relations between
nations have lowered the barriers to outsourcing operations.31 With a population of
over one billion and growing, some have questioned why it would be so attractive for

2009 REPORT ON INT’L TRADE, supra note 16, at Exhibit 6a.
U.S. CENSUS BUREAU, REPORT ON U.S. INTERNATIONAL TRADE IN GOODS AND SERVICES
Exhibit 5 (2010) [hereinafter 2010 REPORT ON INT’L TRADE].
20 Id. at Exhibit 5.
21 Id..
22 Id., at Exhibit 5.
23 2009 REPORT ON INT’L TRADE, supra note 16, at Exhibit 6a.
24 See
Advanced
Technology
Product
Definitions,
U.S.
CENSUS
BUREAU,
http://www.census.gov/foreign-trade/reference/glossary/a/atp.html#general (last visited June 5,2012)
(including as part of its General Advanced Technology Product Definitions Biotechnology, Life
Science, Opto-Electronics, Information & Communications, Electronics, Advanced Materials,
Aerospace, and Nuclear Technology).
25 Id.
26 Id.
27 2009 REPORT ON INT’L TRADE, supra note 16, at Exhibit 6a.
28 See Kamal Nath’s Statement on the Ordinance Relating to Patents (Third) Amendment (Dec.
27, 2004), available at http://commerce.nic.in/pressrelease/pressrelease_detail.asp?id=1309
(indicating Kamal Nath’s, Union Cabinet Minister of Commerce and Industry, views on the positive
economic effects of the TRIPS agreement and India’s amendments to its patent laws).
29 See Joseph Straus, Bargaining Around the TRIPS Agreement: The Case for Ongoing PublicPrivate Initiatives to Facilitate Worldwide Intellectual Property Transactions, 9 DUKE J. COMP. &
INT’L L. 91, 94–99 (1998) (discussing companies which allocate manufacturing overseas).
30 Id. (discussing companies which allocate research and development overseas). This article
also emphasizes the importance of there being no discrimination based on country of origin for
international trade. Id.
31 See Mark B. Baker, “The Technology Dog Ate My Job”: The Dog-Eat-Dog World of Offshore
Labor Outsourcing, 16 FLA. J. INT’L. L. 807, 814–18 (2004) (outlining some of the advantages and
disadvantages of outsourcing, including labor wages); see also Michael G. Owen, Legal Outsourcing
to India: The Demise of New Lawyers and Junior Associates, 21 PAC. MCGEORGE BUS. & DEV. L. J.
175, 176 (2008) (discussing the current state of the legal industry and pros and cons of outsourcing
legal work to India).
18
19
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a company to market its products in India, and conduct manufacturing operations
there.32
B. Territoriality of Patent Laws
In order to be able to develop, manufacture, or sell a product in a particular
country, it is crucial to understand the local patent laws.33 Patent laws are
territorial, in that they do not extend outside the territory where they have been
granted.34 This necessitates a detailed examination of the patent laws in India and
the United States to understand the extent of the rights granted by a patent in each
country, respectively.
C. The United States Patent Law
The United States has had a statutory scheme governing patents since the
adoption of the United States Constitution.35 The Constitution empowered Congress
to create laws on patents.36 The current iteration of patent laws rests in the America
Invents Act (“AIA”).37 The United States Patent and Trademark Office is the body
which reviews and grants patents.38

32 See Janice M. Mueller, The Tiger Awakens:
The Tumultuous Transformation of India’s
Patent System and the Rise of Indian Pharmaceutical Innovation, 68 U. PITT. L. REV. 491, 495 (2008)
(noting India as the world’s largest democracy); see also Mark Landler, ‘India Everywhere’ in the
Alps, N.Y. TIMES, Jan. 17, 2006, at C3 (contrasting India’s free-market democracy to China’s
Communist regime).
33 See generally Vincent J. Napoleon, Impact of Global Patent and Regulatory Reform on Patent
Strategies for Biotechnology, 9 PITT. J. L. & POL’Y. 1. 10–12 (2008).
34 See GHOSH, supra note 4, at 228–31; 35 U.S.C. § 154 (2006) (granting to the patentee the
right to exclude others from making, using, selling the patented subject, or importing it to the
United States); Microsoft Corp. v. A T & T, 550 U.S. 437, 454–55 (2007) (noting the court’s
“presumption against extraterritoriality” in patent cases, the court goes on to say, “the presumption
that United States law governs domestically but does not rule the world applies with particular
force in patent law.”); see also Deepsouth Packing Co. v. Laitrap Corp., 406 U.S. 518, 531 (1972)
(“Our patent system makes no claim to extraterritorial effect . . . and we correspondingly reject the
claims of others to such control over our markets.”); Brown v. Duchesne, 60 U.S. 183, 195 (1856)
(“[T]hese acts of Congress do not, and were not intended to, operate beyond the limits of the United
States,” and “the use . . . outside the jurisdiction of the United States is not an infringement of his
rights.”).
35 See 1 Stat. 109 (1790).
36 See U.S. CONST. art. I, § 8, cl. 8 (granting the power to Congress to “Promote the Progress of
Science and useful Arts, by securing for limited Times to . . . Inventors the exclusive Right to
their . . . Discoveries”).
37 Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284 (2011) (to be codified in
scattered sections of 35 U.S.C.) [hereinafter AIA].
38 See 35 U.S.C. § 1 (2006) (establishing the United States Patent and Trademark Office). See
also id., § 2 (vesting the responsibility to grant and issue, and disseminate to the public information
regarding, patents); id., § 3–13.
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The threshold requirement for patentability is that the subject matter of the
patent in question be eligible under section 101.39 If the invention is patentable, it
still must satisfy three substantive requirements: novelty,40 utility,41 and nonobviousness.42 Even if an invention is novel, useful, and non-obvious, there is no
guarantee that a patent will result.43
Once these requirements and other reporting requirements are met,44 a patent
may be granted.45 A U.S. Patent grants the holder right to exclude others from
making, selling, or marketing the product within the territory of the United States,46
for twenty years from the date of application.47 Upon expiration of twenty years from
the date of application, a patentee can generally not prevent others from making,
using, selling, or marketing the patented item within the territory of the United
States.48
D. The Indian Patent Law
Indian Patent Law is based on British Patent Law.49 Substantively, Indian
Patent Law is similar to the United States Patent Law.50 In the United States, an

39 See AIA, § 33 (to be codified at 35 U.S.C. § 101) (noting that the AIA prohibits any patents
from issuing “on a claim directed to or encompassing a human organism.”).
40 Id. § 3(b) (to be codified at 35 U.S.C. § 102) (outlining the following requirements for novelty:
that “the claimed invention was [not] patented, described in a printed publication, or in public use,
on sale, or otherwise available to the public before the effective filing date of the claimed
invention . . . ”).
41 Id. § 33 (to be codified at 35 U.S.C. § 101) (describing the invention or the improvement as
useful).
42 See id. § 3(c) (to be codified at 35 U.S.C. § 103). The AIA describes the requirement for nonobviousness as follows:
A patent for a claimed invention may not be obtained, notwithstanding that the
claimed invention is not identically disclosed as set forth in section 102, if the
differences between the claimed invention and the prior art are such that the
claimed invention as a whole would have been obvious before the effective filing
date of the claimed invention to a person having ordinary skill in the art to which
the claimed invention pertains. Patentability shall not be negated by the manner
in which the invention was made.
Id.
43 See id. § 3(b) (to be codified at 35 U.S.C. § 102) (outlining reasons outside of novelty for a
patent application to be rejected).
44 See 35 U.S.C. §§ 21–26 (2006); see also 35 U.S.C. §§ 131–67.
45 U.S. PAT. & TRADEMARK OFFICE, U.S. DEP’T OF COMMERCE, MANUAL OF PATENT EXAMINING
PROCEDURE § 700 et. seq. (8th ed. 8th rev. 8, July 2010).
46 See 35 U.S.C. § 154.
47 Id. The Patent Act also provides for extension of the term of the patent provided that certain
conditions are met. Id. § 154(b).
48 See id. § 154.
49 See Martin J. Adelman & Sonia Baldia, Prospects and Limits of the Patent Provision in the
TRIPS Agreement: The Case of India, 29 VAND. J. TRANSNAT’L L. 507, 518–19 (1996) (outlining the
history of the development of the Indian Patent Law).
50 Compare 35 U.S.C. §§ 101–102 to The Patents (Amendment) Act, No. 38 of 2002, INDIA CODE
(2002), § 3 [hereinafter Indian Patent Act of 2002].
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invention has to fall under one of the categories of patentable subject matter.51 In
addition, the Indian Patent Law imposes three substantive requirements on
inventions in order to be patented:52 novelty,53 utility,54 and an “inventive step.”55
A significant difference between the patent laws of the United States and India
is the requirement that a patent be worked within the territory.56 Failure to do so
may result in the grant of a compulsory license.57 After the grant of a compulsory
license, it is possible for a patent to be revoked altogether.58
E. TRIPS, the PCT, and the Doha Declaration
The content of TRIPS was negotiated from 1986 to 1994 and finally signed on
April 15, 1994.59 The purpose behind TRIPS is to harmonize the patent laws for
member nations.60 In addition to patents, the treaty covers copyright, trademark,
and other intellectual property rights.61 TRIPS is enforced by the World Trade
Organization (“WTO”).62 At its foundation, TRIPS requires member nations to treat
51 See Indian Patent Act of 2002, § 4 (outlining as unpatentable inventions “the primary or
intended use . . . of which would be contrary to public order or morality or which causes serious
prejudice to human, animal or plant life or health or to the environment,” as well as a “business
method . . . per se.”).
52 Id., § 3.
53 Id.
54 Id. (defining utility as being “capable of industrial application,” which is further defined as
“capable of being made or used in industry.”).
55 Id. (defining “inventive step” as “a feature of an invention that involves technical advance as
compared to the existing knowledge or having economic significance.”).
56 See Indian Patent Act, § 84 (linking the requirements of affordability and working the patent
within the territory of India):
At any time after the expiration of three years from the date of the sealing of a
patent, any person may make an application to the Controller for grant of
compulsory licence on patent on any of the following grounds, namely: . . .
(b) that the patented invention is not available to the public at a reasonably
affordable price, or
(c) that the patented invention is not worked in the territory of India.
Id.
57 See Indian Patent Act of 2002, § 84. See also Rajnish Kumar Rai, Scare of Avian Flu Revisits
India: A Bumpy Road Ahead, 8 PITT. J. TECH. L. & POL’Y. 7, 7 (2008) (noting that India has “one of
the broadest and most comprehensive compulsory licensing systems,” going “much beyond national
emergency . . . public health . . . and anti-trust situations.”).
58 See Indian Patent Act, § 85 (outlining the process for loss of patent right completely):
Where, in respect of a patent, a compulsory licence has been granted, the Central
Government or any person interested may, after the expiration of two years from
the date of the order granting the first compulsory licence, apply to the Controller
for an order revoking the patent on the ground that the patented invention has not
been worked in the territory of India.
Id.
59 See TRIPS, supra note 6.
60 See id., art. 1 (“members shall be free to determine the appropriate method of implementing
the provisions of this agreement within their own legal system and practice.”).
61 See generally id., part II, sec. 1 (covering copyright protection); Id., part II, sec. 2 (covering
trademark protection).
62 See WTO Agreement, supra note 3, art II.
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all member nations equally with regards to intellectual property rights.63 TRIPS
imposes a patent protection period of 20 years.64 Further, it requires member
nations to confer the same rights to member nations that they have granted to nonmember nations.65
TRIPS imposes substantive requirements for patent grants which track the
patent laws of the United States and India, among others.66 The three substantive
requirements are novelty,67 an “inventive step”,68 and capability of industrial
application.69 Patentable subject matter is left up to member nations.70 Importantly,
TRIPS explicitly authorizes compulsory licensing.71 In addition, it provides certain
exclusive rights that shall be conferred with a patent.72
TRIPS is further modified by the Doha Declaration.73 The Doha Declaration was
promulgated by the Ministerial Conference on November 14, 2001.74 One of the
topics discussed at the Doha Ministerial Conference was public health.75 The Doha

63 TRIPS, supra note 6, art. 3 (describing “national treatment,” article 3 says “each member
shall accord to the nationals of other Members treatment no less favourable than that it accords to
its own nationals with regard to the protection of intellectual property”). The TRIPS agreement
goes further, requiring “most-favored nation” treatment for its member nations. Id., art. 4. “Mostfavored nation” is defined as follows: “with regard to the protection of intellectual property, any
advantage, favor, privilege or immunity granted by a member to the nationals of any other country
shall be accorded immediately and unconditionally to the nationals of all other members.” Id.
64 Id., art. 33 (setting term of protection at twenty years from the date of filing an application).
65 Id., art. 4.
66 Id., art. 28.
67 Id.
68 Id. (defining the term “inventive step” to be synonymous with “non-obvious”).
69 Id. (defining the term “capable of industrial application” as synonymous with the term
“useful”).
70 Id., art. 27 (describing generally the requirements for patentability, and granting member
nations the right to exclude from patentability inventions that it would be necessary to prevent in
the interest of public order, morality, to protect human life, or to protect the environment).
71 Id., art. 31 (authorizing the issuance of compulsory licenses, but imposing various
safeguards):
[E]ach compulsory license has to be considered on its merits; the proposed user
has to have made unsuccessful efforts to obtain authorization on fair terms prior
to the grant of the compulsory license, with the exception of the cases of natural
emergency or “other situations of extreme urgency;” the scope will be limited to
the reason for the grant of the compulsory license; the license will not be
exclusive; the license will not be assignable; the license should be terminated
when the conditions for its grant cease to exist; the right-holder will be paid; and
the grant and terms of the license will be subjected to judicial review.
Id.
72 Id., art. 28 (breaking down patent rights conferred by product and process, and conferring
the rights to exclude from making, using, offering for sale, selling, or importing, products without
the owner’s consent; and conferring the rights to exclude from using the process, and to exclude
others from selling, offering for sale, or importing the product obtained by the process in the case of
a process patent).
73 See Doha Declaration, supra note 7.
74 Id.; see also WTO Agreement, supra note 3, art. IV (describing the make-up of the
Ministerial Conference, to consist of representatives of all members, and prescribing that the
Ministerial Conferences shall take place at least once every two years).
75 Id.
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Declaration authorizes compulsory licensing in stronger terms than TRIPS,
especially as the compulsory licensing pertains to public health.76
The Patent Cooperation Treaty (“PCT”) is an international treaty governing
patent application itself.77 Established in 1970, the PCT was most recently revised in
2001.78 The PCT provides for an international patent application.79 The PCT also
provides for international searches.80 To accomplish the international application
and search, the PCT establishes an international search authority.81 The application
is then reviewed by the international patent review body.82 These three treaties and
administrative bodies work together to attempt to harmonize the patent process and
patent laws around the world.
II. ANALYSIS
This section will first analyze the meaning of the local working provision of the
Indian Patent Law, and how this definition is informed by international treaties,
decisions, and other sections of the patent law. The section will then analyze the
impact of the local working requirement on an American corporation. Finally, this
section will analyze the legality of the local working requirement within the TRIPS
framework.

76 Doha Declaration, supra note 7, para. 5 (iterating that “each member has the right to grant
compulsory licenses and the freedom to determine the grounds upon which such licenses are
granted,” and that “each member has the right to determine what constitutes a national
emergency”); see also id. 7, para. 6 (requiring the Council for TRIPS to devise a solution for countries
who have no or insufficient manufacturing capabilities and thus granting compulsory licenses would
not help in providing product).
77 See Patent Cooperation Treaty, June 19, 1970, 28 U.S.T. 7645, 1160 U.N.T.S. 231 (amended
2001), available at http://www.wipo.int/pct/en/texts/pdf/pct.pdf [hereinafter PCT].
78 Id.
79 Id., art. 3 (describing the requirements of the international application). See also id., art. 4.
80 See id., art. 15 (describing the international search process). See also id., art. 16 (describing
the international search authority); id., art. 17 (describing the procedure before the international
search authority); id. art. 18 (describing report generated by the international search authority).
81 See id., art. 16.
82 See generally id., ch. II (regarding the International Preliminary Examination process); id.,
art. 31 (describing the process by which the preliminary examination is requested); id., art. 32
(describing the body that will be performing the preliminary examination); id. art. 33, para. 1
(describing the preliminary examination as being a “non-binding opinion on the questions whether
the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), and to be
industrially applicable.”); id., art. 33, paras. 2–4 (describing novel as not anticipated by the prior art;
involving an inventive step as being “not, at the prescribed relevant date, obvious to a person skilled
in the art;” and industrially applicable as capable of being “made or used . . . in any kind of
industry.”); id., art. 35 (describing the contents of the preliminary report, and noting that the report
will not state whether or not the claimed invention is patentable according to any national law, but
will indicate whether it finds each claim to be novel, involve an inventive step, and industrially
applicable).
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A. The Meaning of “Working in the Territory of India”
The first point to be analyzed is the meaning of section 84 of the Indian Patents
Act, requiring that a patent be worked in the territory of India.83 On its face, section
84 does not give any guidance regarding the meaning of local working.84 However,
taken together with section 89, the local working requirement will not be satisfied by
importation alone.85
The recent grant of a compulsory license to Natco
Pharmaceutical Limited (“Natco”) on one of Bayer’s patented pharmaceuticals
confirms this suspicion.86 The Controller of Patents granted Natco a compulsory
license on Bayer’s patents because, inter alia, the quantities imported by Bayer were
“grossly inadequate,” priced out of most Indian patients’ means, and Bayer does not
manufacture the drug in India.87 The Controller applied the standard, “worked to
the fullest extent that is reasonably practicable” to Bayer’s practices,88 but only
stated this standard at the beginning and the end of his analysis on the local working
requirement.89 During his analysis of the issue of the local working requirement, the
Controller stated that: “[s]ection 83(b) states that patents are not granted merely to
enable patentees to enjoy a monopoly for importation of the patented article. Upon a
reading of this provision, it becomes amply clear to me that mere importation cannot
amount to working of a patented invention.”90 Section 27 of TRIPS, however, seems
to indicate that this result should not be the case.91 If read together with article 27 of
TRIPS, importation should satisfy the local working requirement of the Indian
Patent Law.92 India’s Manual of Patent Practice and Procedure (“MPPP”) provides
additional guidelines for the patent controller to consider when entertaining an
application for a compulsory license.93 Both the Indian Patent Law and the MPPP
explicitly recognize that patent rights should not be granted solely for the purpose of
importation.94 Therefore, the local working requirement within the Indian patent
system excludes requires local manufacturing.95

See Indian Patent Act, § 84.
Id.
85 See Indian Patent Act, § 89.
86 See Natco Pharma. Ltd. & Bayer Corp. (Mar. 12, 2012) (India).
87 Id. The Controller found the small volumes of the drug imported into the country to be
“neglectful . . . as far as India is concerned.” Id. In terms of availability, the Controller found that
“the mandate of law is not just to supply the drug in the market but to make it available in a
manner such that [a] substantial portion of the public is to reap the benefits of the invention.” Id.
88 Id.
89 Id.
90 Id. The Controller also found that patentees are “obliged to contribute towards the transfer
and dissemination of technology.” Id. The only options for a patentee to “work” a patent in India
are to manufacture it in India, or to grant a license so that another party can manufacture the
invention in India. Id.
91 TRIPS, supra note 6, art. 27.
92 See Indian Patent Act, § 84. See also, TRIPS, supra note 6, art. 27.
93 See Indian Patent Office, Manual of Patent Practice and Procedure (2008) [hereinafter
MPPP], available at http://www.ipindia.nic.in/ipr/patent/manual/main%20link.htm.
94 See TRIPS, supra note 6, art. 27 (stating that patent rights shall be enjoyable without
discrimination as to the place of invention or the field of technology).
95 See Natco Pharma. Ltd. & Bayer Corp. (Mar. 12, 2012). See also MPPP, supra note 93;
Indian Patent Act, § 89.
83
84
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B. Is a Local Working Requirement Legal under TRIPS?
The next point to analyze is the legality of India’s local working requirement
within the TRIPS framework. Article 27 of the TRIPS agreement does not allow
discrimination based on the place of invention.96 Article 27 also does not allow
discrimination based on whether the products are imported or locally produced.97 On
its face, the TRIPS agreement seems to prohibit a local working requirement which
only protects patents that are manufactured within the nation, denying protection to
patented products which are only imported into the nation.98 However, article 30
also permits limited exceptions to the exclusive rights conferred by grant of a
patent.99 In addition, article 31 of the TRIPS agreement permits certain uses, such
as compulsory licenses, without the authorization of the patent holder.100
C. Dispute Settlement Board Decisions
The WTO Dispute Settlement Board (“DSB”) is the adjudicative body of the
WTO that handles disputes.101 To date, the DSB has heard thirty-one cases
pertaining to the TRIPS agreement.102 Ten of the disputes have pertained to article
27 of the TRIPS agreement.103 None have pertained to article 30 of the TRIPS
agreement.104 Three have pertained to article 31 of the TRIPS agreement.105 The
United States brought forward six of the ten disputes pertaining to article 27.106
In DS196,107 the United States alleged that Argentina did not include
safeguards while granting of compulsory licenses on the basis of inadequate
working.108 This dispute was ultimately not decided by the DSB, as both the United
See TRIPS, supra note 6, art. 27.
Id.
98 Id.
99 Id., art. 30 (allowing members to provide “limited exceptions” to the rights conferred by
patents, provided that the exceptions don’t unreasonably interfere with “normal exploitation of the
patent” and do not “unreasonably prejudice the legitimate interests of the patent owner,” all while
taking into account he legitimate interests of third parties).
100 Id., art. 31 (allowing “other use without authorization of the right holder,” subject to
limitations such as unassignability, non-exclusivity, and a hearing on the merits of the request).
101 See WTO Agreement, supra note 3, art. IV.3 (establishing the Dispute Settlement Body of
the World Trade Organization). See also id., annex 2 (describing the authority granted to the DSB,
describing the consultation process, and describing the makeup of the DSB and general provisions
concerning the DSB). See also THOMAS A. ZIMMERMAN, NEGOTIATING THE REVIEW OF THE WTO
DISPUTE SETTLEMENT UNDERSTANDING (2006).
102 See Dispute Settlement:
Index of Disputes by Agreement Cited, WORLD TRADE ORG.,
http://www.wto.org/english/tratop_e/dispu_e/dispu_agreements_index_e.htm?id=A26#selected_agree
ment (last visited June 5, 2012) (listing all disputes made citing the TRIPS agreement).
103 Id.
104 Id.
105 Id.
106 Id.
107 See Argentina – Certain Measures on the Protection of Patents and Test Data (U.S. v.
Argentina),
Dispute
DS196
(WT/DS196/1)
(June
6,
2000),
available
at
http://www.wto.org/english/tratop_e/dispu_e/cases_e/ds196_e.htm.
108 Id.
The complaint alleged that Argentina violated its TRIPS obligations on numerous
grounds, including failure to protect unfair uses of data that must be disclosed as part of regulatory
96
97
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States and Argentina mutually agreed that Argentina’s compulsory licensing
provisions were compliant with TRIPS.109
Two disputes were brought relating to the same transaction. DS408, lodged by
India against members of the European Community, had to do with seizure of
infringing articles at ports in Europe, and has not yet been decided by the DSB.110
DS409 is part of DS408, but was brought forward by Brazil, with respect to generic
drugs imported from India.111 Both DS408 and DS409 have been joined by Brazil,
Canada, China, Ecuador, Japan, and Turkey.112
In 2000, the DSB had occasion to make a decision on whether local working
requirements are legal within the TRIPS framework.113 The United States disputed
a provision in Brazil’s patent law requiring local working of patents in Brazil in
DS199.114 The DSB ultimately did not have to make a decision on the complaint
made by the United States, as Brazil and the United States resolved the dispute
among themselves and the United States withdrew the complaint.115 The United
States and Brazil, however, did agree that Brazil would confer with the United
States prior to making compulsory licensing decisions that affected corporations from
the United States.116
The DSB also had occasion to declare how far TRIPS article 30 extends in 1997,
with DS114.117 Canada’s patent laws provided that pharmaceutical producers could
use products patented by others for regulatory purposes, such as obtaining approval

approvals; improperly excluding microorganisms from patentability; failure to provide for
preliminary injunctions to prevent infringement during trial; failure to protect product-by-process
patents and the exclusive right of importation; failure to provide safeguards in granting compulsory
licenses, particularly those granted for failure to work the patent; shifting the burden of proof in
civil proceedings improperly; and failing to provide adequate protection for certain transitional
applications. Id.
109 See id. (including both DS171 and DS196 in the same mutually agreed upon compromise).
110 See European Union and a Member State – Seizure of Generic Drugs in Transit (India v.
E.U.), Dispute DS408 (WT/DS408/1) (May 19, 2010), available at www.worldtradelaw.net/cr/ds4081(cr).pdf. India alleges that the European Union, and the Netherlands in particular, have been
seizing shipments of generic drugs traveling through their ports on patent infringement grounds.
Id. India alleges that these seizures are inconsistent with the 2003 Decision on TRIPS and Public
Health. Id.
111 See European Union and a Member State – Seizure of Generic Drugs in Transit (Brazil v.
E.U.), Dispute DS409 (WT/DS409/1) (May 19, 2010), available at www.worldtradelaw.net/cr/ds4091(cr).pdf. Brazil’s complaint mirrors India’s complaint. Id. However, Brazil’s complaint differs in
that it places itself and “third countries” as the eventual recipients of the generic drugs originating
in India. Id.
112 See European Union and a Member State – Seizure of Generic Drugs in Transit (India v.
E.U.),
Dispute
DS408
(WT/DS408/8)
(June
18,
2010),
available
at
http://trade.ec.europa.eu/doclib/docs/2011/january/tradoc_147471.pdf (noting the European Union’s
acceptance of Canada, China, Ecuador, India, Japan, and Turkey to join the consultations).
113 See Brazil – Measures Affecting Patent Protection (U.S. v. Brazil), Dispute DS199
(WT/DS199/1)
(June
8,
2000),
available
at
http://www.wto.org/english/tratop_e/dispu_e/cases_e/ds199_e.htm.
114 Id.
115 Id.
116 Id.
117 See Canada – Patent Protection of Pharmaceuticals (E.C. v. Canada), Dispute DS114
(WT/DS114/1)
(Jan
12,
1998),
available
at
http://www.wto.org/english/tratop_e/dispu_e/cases_e/ds114_e.htm [hereinafter Canada 1998].
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for a generic.118 In addition, the patent laws provided for a “stockpiling” exception to
the patent protection on making and using another’s patented invention six months
prior to expiration of the patent.119 During this dispute, the DSB found that the
grant of compulsory licenses is subject to the section 27 requirement that prohibits
discrimination based on place of invention.120 Furthermore, the DSB accepted both
Canada’s and the European Union’s advanced definitions of working the patent,
which included sale and licensing of patented items.121
Although many disputes that made their way through the DSB were ultimately
resolved outside of the dispute process, two of the cases contain information useful in
determining whether India’s local working requirement is legal under TRIPS.122
Applying the definition put forward by both Canada and the European Union in
DS114, a requirement of local working of a patent which encompasses selling locally
would not literally violate of the TRIPS agreement.123 However, continuing with the
DSB’s further statements, that article 27 prohibits discrimination as to whether
products are imported or produced locally, appears to definitively rule that local
working requirements which limit the definition of local working to manufacturing
are against TRIPS.124 The board goes one step further, inferring that the text of
article 27.1 implies that a local working provision may go against the spirit of the
TRIPS agreement.125 So, according to the DSB history, a local working requirement
would probably not comply with the letter or the spirit of the TRIPS agreement.126

118 Id. The contested provision of the Canadian patent law permitted a third party to use a
patented invention to carry out tests required for marketing approval of a patented pharmaceutical
prior to the expiration of the patent, without the rights-holder’s consent. Id.
119 Id. The contested provision of the Canadian patent law permitted a third party to stockpile
the patented item for six months prior to the expiration of the patent. Id. The third party would
then be able to sell the now off-patent item immediately upon expiration of the patent. Id.
120 See id. The panel went on to say, “article 27.1 prohibits discrimination as to enjoyment of
‘patent rights’ without qualifying the term,” and continues, saying, “the acknowledged fact that the
[a]rticle 31 exception for compulsory licences and government use is understood to be subject to the
non-discrimination rule of 27.1.” Id, at 170.
121 See Canada – Patent Protection of Pharmaceuticals (E.C. v. Canada), Dispute DS114
(WT/DS114/R) (Mar. 17, 2000), available at www.wto.org/english/tratop_e/dispu_e/7428d.pdf
[hereinafter Canada 2000).
122 See Brazil, supra note 113; Canada 1997, supra note 117.
123 See Canada 2000, supra note 121.
124 Id. The panel stated, “article 27 prohibits only discrimination as to the place of invention,
the field of technology, and whether products are imported or produced locally.” Id., at 172.
125 See id. Speaking specifically on discrimination as to the field of technology, the panel stated
that “to the extent the prohibition of discrimination does limit the ability to target certain products
in dealing with certain . . . national policies . . . that fact may well constitute a deliberate limitation
rather than a frustration of purpose.” Id. at 171 (emphasis added). The panel went further, saying
that “it is quite plausible, as the EC argued, that the TRIPS agreement would want to require
governments to apply exceptions in a non-discriminatory manner, in order to ensure that
governments do not succumb to domestic pressures to limit exceptions to areas where right holders
tend to be foreign producers.” Id. at 171.
126 See India – Patent Protection for Pharmaceutical and Agricultural Chemical Products,
Dispute
DS79
(E.U.
v.
India)
(WT/DS79/R)
(1996),
available
at
www.wto.org/english/tratop_e/dispu_e/79r.pdf (stating that DSB decisions are not binding on
subsequent panels, but may be considered).
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D. Impact of Local Working Requirement on Patented Inventions
The final point to be analyzed is the effect of the Controller of Patents’
interpretation of the local working requirement on the different phases of an
American corporation’s product. Since importation will not satisfy the local working
requirement, three years after grant of the patent, a party will be able to successfully
obtain a compulsory license if a foreign company’s only commercial activity in India
consists of importing the patented good.127 That local party could successfully seek
and obtain a compulsory license on the foreign company’s patent while it is still
importing its product and prior to beginning manufacturing operations in India,
provided that it has not commenced manufacturing operations within three years of
grant of the patent. If, however, importation does satisfy the local working
requirement, a foreign company will be able to defend the patented item from
compulsory licensing.128 The Controller of Patents’ current interpretation of India’s
local working requirement seems to be violative of India’s TRIPS commitments.
However, TRIPS is a treaty that is based on compliance.129 As such, it is not
guaranteed that the Indian patent office will interpret the TRIPS provisions or its
own patent law in compliance with TRIPS. Therefore, it is most likely that the
foreign company will lose its patent rights to an applicant for a compulsory license
after three years pass and it is still only importing its product, with the possibility of
complete loss of right after an additional two years. Clarification of India’s patent
provision requiring local working will help the foreign company understand its rights
over its patents in India.
III. PROPOSAL
The TRIPS framework has been a part of international law for approximately
ten years.130 In addition, India’s patent amendments bringing the Indian Patent Law
into compliance with TRIPS have been in effect for the past five years.131
TRIPS is a living document, as evidenced by the modifications that are in the
process of ratification embodied in the Doha Declaration.132 A good way to put
pressure on India133 to make the country more open to outside investment in the
patent system would be a change to the TRIPS agreement itself. Such a change will
clarify the expectations of foreign companies seeking to invest in India. A working
framework for determining the appropriateness of granting a compulsory license
would serve to encourage foreign companies to apply for patents and conduct
business in India. In addition, modifying the TRIPS agreement will impact all

See Indian Patent Act, § 84.
See, e.g., Canada 2000, supra note 121.
129 See TRIPS, supra note 6, art. 1 (giving members the authority to implement whatever
methods they deem appropriate to come into compliance with the TRIPS agreement).
130 See id. (noting signed date of Apr. 15, 1994).
131 See Indian Patent Act 2005 (noting signed date of Apr. 5, 2005).
132 See Doha Declaration, supra note 7 (noting adoption date of Nov. 14, 2001).
133 And other countries which have compulsory licensing procedures centered around local
working requirements.
127
128
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member nations, and provide some of the same by-products as those provided to
India.
First, a clause in TRIPS defining local working will be part of an appropriate
solution to the ambiguity surrounding TRIPS’ stance on the local work requirement.
The definition of local working should be satisfied by on-shore manufacturing, as well
as importing, licensing to import, licensing to manufacture, and licensing to sell
within the country.134 By defining local working within the TRIPS agreement,
individual signatories will be unable to dispute the legality of a local working
requirement imposed by another nation, and individual signatories will also be forced
to adhere to a single interpretation of the meaning “worked in the territory.” This
will give a certain degree of confidence to foreign inventors when choosing to pursue
patent applications in countries that have local working requirements.
The second requirement would be a clause in TRIPS requiring countries
granting compulsory licenses to first confer with the government of the corporation’s
home country and report to an international review board prior to granting a
compulsory license.135 This would give both countries an equitable forum in which to
voice concerns.136
This would be an appropriate solution for a number of reasons. First, requiring
a “face-to-face” meeting between the two countries most interested in the protection
or exercise of the patent would strike a balance between the interests of the two
countries. Coupling this with reporting to a review board would place a check on
countries with disparate bargaining power exerting excessive influence on others.
Both countries would have an opportunity to voice concerns over why the rights
should continue to be protected as monopoly rights, and what public interests play
into the request for a compulsory license. Second, the review process would further
the stated mission of the TRIPS agreement, which was established to “reduce
distortions and impediments to international trade.”137 Third, requiring a bilateral
review of compulsory licensing requests would force an international dialogue
134 This amendment would be most appropriate as part of article 27 of the TRIPS agreement,
immediately at the end of section 1, and should read as follows:
A patent will be considered to be worked within a territory if it is manufactured
within the territory, sold within the territory, licensed for sale within the
territory, licensed for manufacture within the territory, or imported to the
territory.
135 The proposed amendment will modify article 31 of the TRIPS agreement, and add the
following language:
(m) when the rights holder is the national of another signatory nation, the nation
seeking to grant the compulsory license must confer with the home nation of the
rights holder prior to such use.
and
(m)(i) the results of such conferences will be reported to the Council on TRIPS.
(m)(ii) the Council on TRIPS will review the conference records annually.
136 See Brazil, supra note 113.
137 See TRIPS, supra note 6, preamble (noting that the TRIPS agreement desires to “reduce
distortions and impediments of trade,” a “need to promote effective . . . protection of intellectual
property rights,” and that the “procedures to enforce intellectual property rights do not . . . become
barriers to . . . trade”). See also id., art. 7 (indicating that “intellectual property rights should
contribute to the promotion of . . . innovation and . . . transfer and innovation of technology,” “to the
mutual advantage of producers and users . . . conducive to social and economic welfare.”) (emphasis
added).
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between nations that would have the potential to further the underlying policy
behind TRIPS.138 Fourth, there is international precedent already existing in the
accords reached between the United States and Brazil on this same requirement,
founded upon Brazil's local working requirement and establishing that the two
countries will confer with one another when granting compulsory licenses on patents
belonging to persons originating in the other.139 Also, adding a requirement that the
countries confer with one another prior to granting compulsory licenses, and provided
that countries do in fact follow this process, will create a body of international
records that will help to inform parties when making decisions to patent overseas.
Finally, requiring that conference results be reported to the WTO for review will get
an extra set of eyes looking at the final agreement, which will potentially help
develop future policy regarding compulsory licensing.
This change to the TRIPS framework, however, cannot be implemented without
overcoming a number of obstacles. The first issue confronting a proposed change to
TRIPS is the history behind the drafting of TRIPS.140 During the negotiation of the
TRIPS agreement, the local working requirement, in particular, was hotly contested
between different nations who had alternate approaches to a local working
requirement and different national interests.141 In addition to the substance, the
particular wording will become an issue with one hundred and fifty three signatory
nations being a party to the TRIPS agreement.142
The second hurdle that an amendment to TRIPS will face is a procedural hurdle:
the requirement that two thirds of the signatory parties must ratify an amendment
to TRIPS.143
This sets up the third obstacle, which is brought about by the nature of the
TRIPS agreement: actual implementation.144 India, for example, took almost ten
years between signing onto the TRIPS agreement and implementing all of its
requirements.145
The fourth issue facing any amendments to the TRIPS agreement is the
existence of competing domestic interests of the individual signatories.146 A
developed country and a developing country will have different objectives and
interests involving patent rights, particularly as countries get closer to the opposite
ends of the spectrum.

Id.
See Brazil, supra note 113.
140 See, e.g., Paul Champ & Amir Attaran, Patent Rights and Local Working Under the WTO
TRIPS Agreement: An Analysis of the U.S. - Brazil Patent Dispute, 27 YALE J. INT’L L. 365, 373–80
(2002) (describing the negotiation process).
141 Id.
142 See WORLD TRADE ORG., http://www.wto.org (follow the hyperlink titled “153 members” for
a list of all 153 member countries).
143 See WTO Agreement, supra note 3.
144 See TRIPS, supra note 6, art. 1 (noting that “members shall give effect to the provisions of
[TRIPS]”); see also id., art. 8 (noting that members can adopt “measures necessary to protect public
health”).
145 See Indian Patents Act of 2005.
146 A very wealthy country, for example, will have drastically different concerns in the area of
intellectual property rights, from a very poor country struggling to feed its citizenry.
138
139
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A fifth obstacle is rooted in the legislative history behind TRIPS itself.147 A
consensus was not reached during the Uruguay round with regards to the inclusion
or exclusion of a local working requirement.148 It is possible that this same deadlock
will face the WTO as it attempts to amend the text of the TRIPS agreement to make
it more difficult for countries to grant compulsory licenses.149 In addition, a change
requiring that two nations meet and report the meeting to the WTO will likely meet
similar criticism to that met by the Doha declaration, namely that the requirements
are too onerous to pursue a compulsory license.150
Despite these obstacles, an amendment to TRIPS still appears to be the best
solution to address the concerns of foreign companies who are trying to develop
global marketing or outsourcing plans. The problems presented by amendment to an
international treaty like TRIPS are surmountable if the WTO dedicates itself to
negotiation and resolution of the amendment, and potential catching points are
outweighed by the benefits. Many companies which want to conduct business in
India will want to know what they are getting into before embarking on its plan to
develop, manufacture, and sell products in India. In addition to understanding the
patent laws of India, having the relevant provisions pertaining to the company’s
rights and knowing that there is a safety valve in case of an application for
compulsory license will serve to assure similarly situated corporations that their
patented inventions will be protected outside of the United States, and in turn, to
increase their investment in countries like India.
IV. CONCLUSION
In the past fifteen years, TRIPS became a part of international law and signed
on to by one hundred fifty-three countries.151 The United States and India are two

147 See Communication from Argentina, Brazil, Chile, China, Colombia, Cuba, Egypt, India,
Nigeria, Peru, Tanzania, Uruguay, and Pakistan, part II, chap. II, art. 5, GATT Doc.
MTN.GNG/NG11/W/71
(May
14,
1990),
available
at
http://www.wto.org/gatt_docs/English/SULPDF/92100147.pdf.
148 See Champ & Attaran, supra note 140, at 373–80 (describing the negotiation process).
149 This is based on using the legislative history as a real-world example of the negotiating
process and an assumption that the competing interests of signatory nations will fall along similar
lines to the original WTO and TRIPS negotiations.
150 See
Little-used ‘Par.6’ System Will Have its Day, WORLD TRADE ORG.,
http://www.wto.org/english/news_e/news10_e/trip_26oct10_e.htm (last visited June 5, 2012)
(describing proceedings at October 26-27 TRIPS Council meeting). Only one case has been reported
since the Doha declaration and ensuing years, with Canada being the exporter and Rwanda being
the importer. Id. Canada presented its experience implementing the system and in practice in that
one instance during the meeting. Id. A number of countries at the meeting criticized the system as
overly burdensome. Id. India chimed in with an account regarding a recent experience with
compulsory licensing under the Paragraph 6 exception as well. Id. India’s contribution reflected
that an Indian company had sought compulsory licenses in order to export pharmaceuticals to
Nepal. Id. Ultimately, however, the company dropped its request for the compulsory license. Id.
According to the Indian representative, the company dropped its request for a compulsory license
because Nepal “found the conditions for using the system too onerous to proceed.” Id.
151 See WORLD TRADE ORG., http://www.wto.org (follow the hyperlink titled “153 members” for
a list of all 153 member countries).
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innovating nations with large populations that signed on to the TRIPS agreement.152
In its Patent Law, India has included a provision requiring that patents be worked
within the territory of India, or on sale at a reasonable price.153 The legality of a local
working requirement was heavily contested during the drafting of the TRIPS
agreement,154 and the United States has gone on to dispute the legality of more than
one country’s local working requirement since the TRIPS agreement was finalized
and adopted.155 In addition to the local working requirement, the Indian Patent Law
has substantive differences from the patent law of the United States.156 This creates
uncertainty for foreign inventors in India at the outset because a patentable
invention elsewhere may not be patentable in India. In addition, the potential
penalty for failing to work a patent in India is the grant of a compulsory license.157
This compulsory license may ripen into a permanent revocation of the patentee’s
patent rights. A revision to the TRIPS agreement, within the spirit of the agreement,
will be important in order to guarantee further clarity in the rights of parties such as
Megatech Corporation seeking to patent inventions in India as well as other
countries with similar provisions in their patent laws.

152 Id. The United States and India are among the countries that became members on January
1, 1995. Id.
153 See Indian Patents Act 2005, § 84(c) (outlining the local working requirement).
154 See, e.g., Champ & Attaran, supra note 140, at 373–80 (describing the negotiation process).
155 See Brazil, supra note 113 (describing the dispute brought by the United States and the
accord reached by the United States and Brazil to terminate the dispute). See also, Champ &
Attaran, supra note 140, at 373–80.
156 See, e.g., Indian Patent Act, § 3 (requiring “increased efficacy” for patentability).
157 See generally, id., § 84 (outlining possible reasons for granting compulsory licenses,
including the failure of a patent be worked in the territory of India, unavailability of the patented
item in India for a “reasonably affordable price,” and lack of meeting the requirements of the public).
See also, The Patents Act 2005, § 92 (enabling the grant of compulsory licenses for export of
pharmaceuticals to countries that are unable to do so, as authorized by the Doha Declaration); id.
§ 89 (outlining factors that the patent controller should take into account when considering a section
84 application for compulsory license, including the nature of the invention, the amount of time that
has passed since the patent issued, and the actions taken by the patentee in attempting to work the
patent in the territory of India).

